<ul>
<li>Shaanxi Financial Holding’s fund manager New Era Capital-backed Maike Aote (Maike Pharma-B, 2335.HK) listed on HKEX’s Main Board on June 24.     *      Maike Aote became Northwest China’s first innovative drugmaker to list in Hong Kong under the Chapter 18A regime.     *      The company is positioned as a peptide-focused innovator with a pipeline led by one core product, seven clinical-stage candidates, six filed in China and the US. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shaanxi Financial Holding Group Co Ltd published the original content used to generate this news brief on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

02335

<p>Maike Pharma (2335.HK), backed by Shaanxi Financial Holding’s New Era Capital, listed on the HKEX Main Board on June 24. It is Northwest China’s first innovative drugmaker to list under Chapter 18A rules. The company focuses on peptides, with a pipeline including one core product and seven clinical-stage candidates filed in China and the US.</p>

Shaanxi fund-backed Microcure Pharma lists in Hong Kong under Chapter 18A rules